Cysview: What It Is

Cysview is a pharmaceutical product that makes non-muscle invasive bladder cancer tumors glow bright pink under blue light during a cystoscopy. Because the cancer is more visible, urologists can remove it more completely than if they weren’t using Cysview.1 It was approved by the US Food and Drug Administration (FDA) in June 2010.

Indication: Cysview is an optical imaging agent indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder.
Cysview is used with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system to perform Blue Light Cystoscopy (BLC®) as an adjunct to White Light Cystoscopy.

Used in Blue Light Cystoscopy (BLC®) with Cysview®

Urologists who have access to the special equipment needed for this procedure can perform a BLC with Cysview in any medical setting – operating room, hospital outpatient department, ambulatory surgical center, medical clinic or physician’s office. Clinical studies have shown efficacy when used with either a flexible or rigid cystoscope1 – the thin, tube-like telescope that goes into the bladder for the procedure.

BLC® with Cysview® safety profile1

Any procedure may have some risks. Patients should consult their urologist regarding the risks and benefits of this procedure.

The most common adverse reactions reported in patients who received Cysview (≤2% of patients):

  • Bladder spasm
  • Dysuria
  • Hematuria
  • Bladder pain
  • Procedural pain
  • Urinary infection
  • Headache

The following adverse reactions have been voluntarily reported during post-approval use of Cysview. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

  • Anaphylactoid shock
  • Hypersensitivity reactions
  • Bladder pain
  • Cystitis
  • Abnormal urinalysis

No specific drug interaction studies have been performed

Warnings and Precautions:

  • Anaphylaxis: have trained personnel and therapies available.
  • Failed Detection: Cysview may not detect all malignant lesions. Always perform White Light Cystoscopy followed by Blue Light Cystoscopy. Do not biopsy with blue light only.
  • False fluorescence may occur due to inflammation, cystoscopic trauma, scar tissue, previous bladder biopsy, recent BCG therapy or chemotherapy.

1 Cysview [prescribing information]. 2018:1-14.